Yüklüyor......
Targeting the mTOR kinase domain: the second generation of mTOR inhibitors
The mTOR signaling pathway is dysregulated in ~50% of all human malignancies and is a major cancer drug target. Although rapamycin analogs (rapalogs) have shown clinical efficacy in a subset of cancers, they do not fully exploit the antitumor potential of mTOR targeting. Because the mTOR kinase doma...
Kaydedildi:
| Asıl Yazarlar: | , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2011
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3073023/ https://ncbi.nlm.nih.gov/pubmed/21333749 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.drudis.2011.02.008 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|